A patient diagnosed with MOGAD after COVID-19 - A case report
MOGAD (myelin oligodendrocyte glycoprotein antibody disease) is a newly defined inflammatory condition of the central nervous system. The presence of MOG antibodies holds a key role in the identification of the disease, as the detection of these anitbodies points to an inflammatory state with a distinct clinical presentation, specific radiological and laboratory findings, different course and prognosis as well as separate treatment considerations. Simultaneously, during the last two years healthcare worldwide has focused a large part of its resources on the management of COVID-19 patients. The long-term health effects of the infection are still unknown, but a large part of its manifestations are similar to those already seen in other viral infections. A significant percentage of patients who develop demyelinating disorders in the central nervous system presents an acute post-infectious inflammatory process (ADEM). Here we report the case of a young woman who presented a clinical picture compatible with ADEM after SARS-CoV-2 infection that led to a MOGAD diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
Lakartidningen - 120(2023) vom: 21. Feb. |
| Sprache: |
Schwedisch |
|---|
| Weiterer Titel: |
MOG-positivitet i serum och likvor påvisades efter covid-19 |
|---|
| Beteiligte Personen: |
Papastergios, Chrysostomos [VerfasserIn] |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 24.02.2023 Date Revised 02.03.2023 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM353159786 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353159786 | ||
| 003 | DE-627 | ||
| 005 | 20231226055353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||swe c | ||
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353159786 | ||
| 035 | |a (NLM)36809636 | ||
| 035 | |a (PII)22137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a swe | ||
| 100 | 1 | |a Papastergios, Chrysostomos |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A patient diagnosed with MOGAD after COVID-19 - A case report |
| 246 | 3 | 3 | |a MOG-positivitet i serum och likvor påvisades efter covid-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2023 | ||
| 500 | |a Date Revised 02.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a MOGAD (myelin oligodendrocyte glycoprotein antibody disease) is a newly defined inflammatory condition of the central nervous system. The presence of MOG antibodies holds a key role in the identification of the disease, as the detection of these anitbodies points to an inflammatory state with a distinct clinical presentation, specific radiological and laboratory findings, different course and prognosis as well as separate treatment considerations. Simultaneously, during the last two years healthcare worldwide has focused a large part of its resources on the management of COVID-19 patients. The long-term health effects of the infection are still unknown, but a large part of its manifestations are similar to those already seen in other viral infections. A significant percentage of patients who develop demyelinating disorders in the central nervous system presents an acute post-infectious inflammatory process (ADEM). Here we report the case of a young woman who presented a clinical picture compatible with ADEM after SARS-CoV-2 infection that led to a MOGAD diagnosis | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Shaker, Amen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lakartidningen |d 1965 |g 120(2023) vom: 21. Feb. |w (DE-627)NLM000007544 |x 1652-7518 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2023 |g day:21 |g month:02 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2023 |b 21 |c 02 | ||